نتایج جستجو برای: tumorigenesis antiangiogenesis

تعداد نتایج: 25649  

2013
Muhammad Usman Saeed Evangelia Gkaragkani Kashif Ali

The first antivascular endothelial growth factor (anti-VEGF) was developed as an anticancer drug for colonic carcinomas. Since then, anti-VEGFs have developed in scope and indications. They have revolutionized the treatment of exudative macular degeneration and have had a major impact on treatment of several other conditions. This has resulted in an increased number of patients seeking treatmen...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2009
Ting-Yi Juan Steve R Roffler Hsien-San Hou Shih-Ming Huang Kai-Chuan Chen Yu-Lin Leu Zeljko M Prijovich Cheng-Ping Yu Chang-Chieh Wu Guang-Huan Sun Tai-Lung Cha

PURPOSE This study is aimed at investigating the in vivo antitumor activity of a novel cell-impermeable glucuronide prodrug, 9-aminocamptothecin glucuronide (9ACG), and elucidating the synergistically antitumor effects of antiangiogenesis therapy by targeting the tumor microenvironment. EXPERIMENTAL DESIGN We analyzed the antitumor effects of 9ACG alone or combined with antiangiogenic monoclo...

2006
Mahtab Bahramsoltani Sabine Käßmeyer Johanna Plendl

The process of angiogenesis includes sprouting of new vessels from pre-existing ones, their remodelling and regression. Angiogenesis is a pre-requisite for growth and differentiation of organs and tissues as it allows for supply with nutrients and oxygen (Folkman, 2003). Angiogenesis also plays a key role in many pathological processes, particularly growth and metastasis of tumours (Folkman, 19...

Journal: :Nature Reviews Cancer 2004

Journal: :Seminars in Cell & Developmental Biology 2011

Journal: :American Society of Clinical Oncology educational book 2021

Immune checkpoint inhibitors have an established role in the treatment of newly diagnosed metastatic kidney cancer. Treatment regimens combining nivolumab plus ipilimumab, pembrolizumab axitinib, cabozantinib, and lenvatinib demonstrated superior overall survival compared with sunitinib randomized studies. Response rates vary from 42% to 71.1% these combinations. Atezolizumab been approved for ...

Journal: :Nature Reviews Cancer 2004

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید